Newsfeeds - Spark Newswire

2 minute read

Despite Failed Phase 3 Study, FDA Staff Says Biogen’s ALS Drug May Have Clinical Benefit

March 21, 6:59 AM

FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc’s (NASDAQ:BIIB) ALS…

BIIB

2 minute read

(BIIB) – Analyzing Biogen’s Short Interest

By Benzinga Insights

March 17, 11:45 AM

Biogen’s (NASDAQ:BIIB) short percent of float has risen 8.21% since its last report. The company recently reported that…

BIIB

2 minute read

Biogen’s Debt Overview

By Benzinga Insights

March 15, 3:45 PM

Over the past three months, shares of Biogen Inc. (NASDAQ:BIIB) decreased by 7.79%. Before having a look at…

BIIB

1 minute read

Analyst Says Biogen-Eisai’s Alzheimer’s Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity

By Vandana Singh

March 14, 1:34 PM

Eisai Co Ltd (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB) said the U.S. Department of Veteran Affairs (VA) would provide coverage of their…

BIIB

1 minute read

FDA
News

Sage Therapeutics & Biogen Reveal FDA Does Not Currently Plan To Convene Advisory Committee Meeting To Discuss NDA For Zuranolone In Treatment Of Major Depressive Disorder & Postpartum Depression

By Benzinga Newsdesk

March 8, 7:33 AM

Sage Therapeutics, and Biogen announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the

BIIB

1 minute read

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer’s Treatment

By Vandana Singh

March 6, 11:46 AM

The FDA has accepted Eisai Co Ltd (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection,…

BIIB

1 minute read

FDA Accepted Eisai-Biogen’s Supplemental Biologics License Application For Leqembi (Lecanemab-IRMB) 100 mg/ml Injection For Intravenous Use, Supporting The Conversion Of The Accelerated Approval Of Leqembi To A Traditional Approval

By Benzinga Newsdesk

March 6, 4:45 AM

The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is currently planning to hold an Advisory Committee to discuss this application

BIIB

2 minute read

Peering Into Biogen’s Recent Short Interest

By Benzinga Insights

March 1, 3:27 PM

Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that are available for trading.

BIIB

2 minute read

Reported Late Monday Feb. 27, Eisai Co. And Biogen Inc. Announce Biologics License Application For Lecanemab Designated For Priority Review By China National Medical Products Administration

By Happy Mohamed

February 28, 1:56 AM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", , Biogen", , ))))

BIIB